U.S. Residential REITs Stock News

Molson Coors Beverage shares were up 2.3% today and have gained around 12% over the past month. The market liked what it saw on the surface. Revenue for the June quarter came in at US$3.10b and basic earnings per share landed at US$1.24. For a brewer that has been loss making over the last twelve months and is carrying meaningful debt, the real story now is whether this quarter marks the start of a profit rebuild that can eventually support that dividend and narrow the gap between price and...

American Healthcare REIT stock jumped 3.7% to US$56.74 after the Q2 release, a quick reward for holders who had already seen a roughly 10% gain over the past three months. The headline is not the share price. It is cash generation. Normalized funds from operations, or FFO, came in at US$0.54 per diluted share and management lifted full year FFO guidance to US$2.15 to US$2.19. That move in guidance, backed by 13.2% same store net operating income growth, is what matters for anyone thinking...

Collegium Pharmaceutical stock inched up 1.2% to US$29.47 after earnings, a muted move for a company that just swung from a Q1 profit to a Q2 loss. The market focused on the headline net loss of US$15.1m, yet the more important story for you is the margin squeeze behind that number. Revenue in Q2 came in at US$199.9m, supported by the expanding attention deficit hyperactivity disorder portfolio. However, acquisition costs and authorized generics in pain treatments pressured profitability. The...

Payoneer Global’s stock barely moved on the earnings release, slipping less than 1% and sitting near US$7.10. The calm price masks a sharper story. The market is staring at a payments platform that just swung from a US$19.6 million profit in Q1 to a small loss in Q2, while still trading on a rich P/E of 47.8x. That mix of profit pressure and premium valuation is the core tension. The following sections examine whether this quarter’s margin squeeze helps explain the muted reaction, or whether...

vTv Therapeutics stock inched up 2.2% to US$35.37 heading into the first full trading day after earnings, even as the headline told a harsher story. Q2 flipped sharply back into loss making territory, with basic earnings per share swinging to a loss of US$1.05 and revenue dropping to zero after a one off US$36.84m in Q1. The short term relief rally sits against a tougher long term picture. vTv Therapeutics remains unprofitable over the past year. Is vTv Therapeutics trading at a genuine...

Central banks are signalling that policy rates may stay higher for longer as inflation pressures, including energy costs, remain in focus. That keeps cheap capital scarce and puts extra attention on technologies that could reshape computing efficiency, such as quantum computing. This article highlights three stocks from our Quantum Computing Stocks screener that show how different parts of the quantum value chain are trying to position for this backdrop. The three stocks covered next are just...

Celsius Holdings came into this print with a bruised stock chart and a hyped growth story. Over the past three months the share price fell about 14%, yet after Q2 results the stock ripped about 17% higher to US$27.77 in a single session. That move flags how quickly sentiment can flip when numbers reset the narrative. The headline this quarter is profit pressure in the middle of solid top line progress. Revenue reached US$817.9m while basic earnings per share dropped to US$0.14 and net income...

Kelly Services stock slipped 2.8% to US$15.19 in the first trading session after earnings, even though the headline numbers pointed to a cleaner quarter than many investors had grown used to. The company posted Q2 revenue of about US$1.04b and returned to positive earnings per share of roughly US$0.33, with adjusted earnings before interest, tax, depreciation and amortization margin improving to 3%. For a staffing and workforce solutions stock that has been wrestling with losses and modest...

The market reacted positively to DraftKings on the headline, with the stock jumping about 8% to roughly $24 after earnings, even though the quarter swung back to a loss. That move rests on one core idea: investors are treating adjusted EBITDA of $115 million and reaffirmed 2026 guidance of $700 million to $900 million as evidence that the profit story remains intact. Coming into the release, the stock had cooled over the past month and quarter. Today is a sentiment reset built around one key...

Evergy stock barely moved after earnings, ticking up about 0.4% to US$83.38, which suggests the market viewed the report as business as usual. The numbers, however, indicate a more detailed picture. Quarterly earnings per share were about US$0.93 and adjusted earnings per share for the quarter came in at US$0.88, with management reaffirming a US$4.24 full-year adjusted earnings midpoint. That calm price reaction sits alongside a broader consideration. Evergy is trading near 21x earnings while...

Lineage Cell Therapeutics slipped 2.7% to about US$1.10 after its second quarter report, a muted move for a stock that has already shed close to 20% over the past three months. The headline in this print is not the top line. It is the sharp squeeze between a tiny US$1.1 million in quarterly revenue and a much heavier cost base, even though this quarter showed a US$1.5 million net income on paper. That profit figure rests largely on noncash warrant revaluation. The key consideration for long...

Haemonetics stock came into this quarter on a tear, with shares up almost 60% over the past three months and another 3.3% added today. That kind of move sets a high bar. The headline from the print is straightforward: revenue reached US$339.4m and adjusted earnings per share landed at US$1.14, while management pushed full year revenue guidance higher. For a company long viewed as a steady blood and plasma technology compounder, the real story this quarter is not a growth scare. Instead, it is...

Tarsus Pharmaceuticals stock slipped 0.8% to US$64.79 after the Q2 print, a muted reaction for a company that just posted US$173.9m in quarterly net product sales from a single flagship drug. The market focused on another quarterly loss and the near term hit from heavier research and development spending. In the longer term, the story sits in a different place. Revenue over the past year has reached US$606.3m, management has raised 2026 sales guidance for XDEMVY, and the balance sheet held...

Amphastar Pharmaceuticals stock closed up 4.9% at US$20.78, yet the real story sits behind that modest relief rally. Q2 delivered a sharp earnings snapback, with basic earnings per share at US$0.70 on revenue of US$183.9m, and management leaning into share repurchases with about US$45m bought back in the quarter. The market is reacting to the quarter in front of it. The bigger question for you is how this drug maker’s margin pressure, earnings outlook and wide gap to the referenced fair value...

OmniAb walked into this quarter with a reputation as a high multiple, high promise antibody discovery platform, and the stock has just been reminded of that. Shares jumped 37.5% to US$3.08 after the Q2 2026 release, a sharp move for a company that still reports losses but just posted US$13.4m in revenue and a much smaller net loss of US$5.9m. The real story for OmniAb this time is the earnings trend. Losses are shrinking while milestone revenue from partner drugs advancing in the clinic does...

MP Materials stock jumped 7.6% to US$51.11 after earnings, even though the company remained in the red this quarter. The market is reacting to a rare earths story that is now about scale, not quick profits. Revenue reached US$126.1m and adjusted profitability at the earnings before interest, tax, depreciation and amortisation level improved, yet basic earnings per share stayed negative. For short term traders, that mix can feel messy. For long term investors, the real headline is a rare...

Investors Title slipped about 2% today, even though the latest quarter delivered one of its punchiest earnings prints in recent memory. The stock had been grinding higher over the past three months, so this pullback may feel jarring if you came in expecting a clean victory lap. Q2 basic earnings per share of US$7.75 on revenue of US$86.5m reinforced that the title insurer can still generate solid profit in a choppy real estate market. The bigger question now is whether that margin strength...

The market barely shrugged at Realty Income’s earnings, with the stock edging up only 0.2% to about US$62.50, yet the headline from this quarter is quietly bigger. Adjusted funds from operations per share, the key cash flow gauge for a REIT, came in at US$1.09 and management lifted the full year outlook to about US$4.44 to US$4.45. For a stock that has drifted slightly lower over the past month and week, that kind of reaffirmed cash engine and higher guidance is the real story investors will...

Papa John’s International stock barely flinched after earnings, slipping only 0.7% to about US$24.50, even though the story was all about pressure and sacrifice. The headline this quarter is not the modest quarterly profit. It is the decision to suspend the rich 7.5% dividend in order to fund a multi year overhaul while global system sales declined and North America same store sales remained weak. The market reaction so far looks muted compared with that trade off. Investors now have to weigh...

Appian stock ripped higher today, jumping about 14% to US$34.64, as investors rushed to reprice a software platform that just reported another quarter of cloud growth and profit improvement. The headline is simple: cloud subscription revenue reached US$131.7m in Q2 and adjusted earnings before interest, tax, depreciation and amortisation came in at US$16.2m, strong enough for management to lift full year cloud and margin guidance. Short term traders reacted to the beat. Long term holders will...

Rigetti Computing just ripped 8.5% higher in a single session, yet the story behind that move is less euphoric. The headline this quarter is not revenue in isolation. It is the strain between quantum growth ambitions and an unprofitable earnings profile, with Q2 showing a net loss in the tens of millions of US dollars and basic earnings per share back in negative territory. Coming into the release, the stock had already swung sharply over the past three months and carried a rich price to book...

AerSale came into this print already under pressure, with the stock down roughly 10% over the past three months and now dropping another 6% to about US$5.90 after the release. The reaction reflects one thing above all else: profitability is moving the wrong way. Q2 revenue of US$70.9m sat well below the prior year level and the company posted a net loss of US$5.6m, extending the red ink seen earlier in 2026. For an aircraft leasing and maintenance specialist that many investors view as an...

Casella Waste Systems stock slipped about 1% to US$89.41 after its latest earnings, which looks like a mild shrug from the market compared with what the numbers actually say. You are looking at a solid waste operator that just produced US$543.7m in quarterly revenue and US$123.2m in adjusted earnings before interest, tax, depreciation and amortization, or adjusted EBITDA. Management also lifted full year revenue guidance while holding the EBITDA and free cash flow ranges steady. The real...

Airbnb stock just ripped 17% higher in a single session, and that is not the kind of move you usually see without a story to match. The story this time is simple. Revenue hit US$3.6b in the quarter and net income reached US$816m, both comfortably strong for a platform that lives and dies on travel demand and booking volume. The market is treating this as a sentiment reset on Airbnb. A rich P/E and questions about growth momentum were hanging over the stock coming into the print. This earnings...